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Introduction
Heart failure (HF) is a major global health problem, with a 
prevalence of more than 26 million annual cases worldwide.1)2) The 
prevalence is increasing in many countries due to aging societies, 
increased prevalence of risk factors, and better survival from other 
cardiovascular diseases.3-5) However, the survival rate of HF remains 
poor, and the health burden from this condition is increasing 
globally.6-13) The impact of this condition has increased in Korea 
due to the increased growth and development of the society. The 
prevalence of risk factors such as diabetes, myocardial infarction, 
and ischemic heart disease has increased in the past few decades, 
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although the survival outcomes from these diseases have also 
improved.14-16) Consequently, the prevalence of HF approximately 
doubled from 0.75% in 2002 to 0.53% in 2013, and the total 
medical cost increased by about 50% from 2009 to 2013.17)18)
The increase in total medical cost was mostly attributable to the 
cost of in-hospital care. Unfortunately, the serial registry studies 
performed in Korea revealed that the survival from HF has not 
significantly improved during the past decades.11)19)20) This revealed 
an unmet need for a robust investigation of the demographic 
and clinical profiles, diagnostic and therapeutic approaches in 
routine practice, and the degree of adherence to clinical guidelines 
regarding pharmacological and non-pharmacological treatments. 
In addition, it also suggests the need for close examination of 
patients’ clinical outcomes, prognostic factors, and trends over the 
last decade. Therefore, we established a robust registry of acute 
heart failure (AHF) in Korea and compared it with our previous 
registry. 
Subjects and Methods
Patients and data collection
The Korean Acute Heart Failure (KorAHF) registry is a prospective 
multicenter cohort study designed to describe patient demographics, 
clinical characteristics, current treatments, and short-term and 
long-term patient outcomes of AHF. Detailed information on the 
study design and results from interim analysis are described in our 
previous paper.20) Briefly, patients who had signs or symptoms of HF 
and met one of the following criteria were eligible for this study: 1) 
lung congestion or 2) objective left ventricular systolic dysfunction or 
structural heart disease findings. Patients hospitalized for AHF from 
one of 10 tertiary university hospitals throughout the country were 
consecutively enrolled from March 2011 to February 2014. Follow-up 
of the patients is planned until 2018. Data were collected by each site 
and entered into a web-based case-report form in the web-based 
Clinical REsearch and Trial (iCreaT) system from the Korea National 
Institute of Health. Information about patient demographics, medical 
history, signs, symptoms, laboratory test results, electrocardiogram, 
echocardiography, medications, hospital course, and outcomes was 
collected at admission, at discharge, and during the follow-up (30-
day, 90-day, 180-day, 1- to 5-year annually). In-hospital mortality 
and the mode of death were adjudicated by an independent event 
committee. The mortality data for patients who were lost to follow-
up was collected from the National Insurance data or National Death 
Records. The study protocol was approved by the ethics committee/
institutional review board at each hospital. 
Variables and statistical analysis
Descriptive statistics are used to summarize demographic 
and clinical characteristics, clinical care during hospitalization, 
and patient outcomes. Detailed information on the variables 
was described in our previous paper.20) Data are reported as 
mean±standard deviation or median with range for continuous 
variables and as number (percentages) of patients for categorical 
variables. We used Student’s t-test to demonstrate the statistical 
significance of differences between two groups if they showed a 
normal distribution and Wilcoxon rank sum test if they did not. 
Similarly, Chi-square test was used for categorical variables, while 
Fisher’s exact test was used when 20% of the expected frequencies 
were less than 5. The individual participant data from the previous 
registry, the Korean Heart Failure (KorHF) registry, was received and 
approved by the KorHF writing committee. We extracted the data 
from 10 hospitals that participated in both the KorHF and KorAHF 
and summarized the demographic and clinical characteristics, 
clinical care during hospitalization, and outcomes based on 
descriptive statistics.
The logistic regression model was applied to verify predictors 
of in-hospital mortality. A binary model and multinomial model 
were used for all-cause mortality and cardiovascular death or non-
cardiovascular death, respectively. Variables found to be statistically 
significant (p<0.1) in the univariable analysis were included in the 
multivariable model, except for variables with >10% missing values 
or variables that are closely related to other clinical variables and 
so may have multicollinearity issues. The analysis was performed 
using stepwise selection. The C-statistic was 0.865, and the p value 
for the Hosmer-Lemeshow goodness of fit test was 0.2669 for 
the binary multivariable logistic regression model, suggesting that 
our model is appropriate. For all statistical analyses, SAS software 
version 8.2 (SAS Institute Inc., Cary, NC, USA) and R version 3.2.5 
were used. This project was supported by the Medical Research 
Collaborating Center at Seoul National University College of 
Medicine and Seoul National University Hospital.
Results
Demographic and clinical characteristics
We enrolled 5625 AHF subjects from 10 tertiary university 
hospitals in Korea. The mean age was 68.5±14.5 years, and 53.2% 
were male (Table 1). In total 5103 of the enrolled patients were 
available for left ventricular ejection fraction (LVEF) measurement; 
3088 had LVEF that was 40% or less, while 1285 had LVEF greater 
than 50%. More than half of the patients had de novo HF (n=2936, 
52.2%). Hypertension was present in 62.2% of the patients, 
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Table 1. Baseline characteristics, clinical management, and outcomes 
Characteristics Total (n=5625) Survivor (n=5356) In-hospital death (n=269) p
Demographics
Age (years) 68.5±14.5 68.4±14.5 70.5±14.4 0.013*
Male (%) 53.2 53.0 58.4 0.083†
Body mass index (m/kg2) 23.3±3.9 23.3±3.9 22.8±3.8 0.026*
Co-morbidities§ (%)
Hypertension 62.2 62.2 62.1 0.981†
Diabetes 40.0 39.4 51.3 <0.001†
Ischemic heart disease 42.9 42.1 58.4 <0.001†
Atrial fibrillation 28.5 28.7 23.4 0.059†
Chronic lung disease 11.3 11.0 15.6 0.021†
Cerebrovascular disease 15.2 15.0 17.8 0.210†
Chronic renal failure 14.3 14.0 20.8 0.002†
Etiology
Ischemic CMP 37.6 36.8 53.5 <0.0001†
Hypertensive CMP 4.0 4.1 1.5 0.034†
Idiopathic dilated CMP 15.3 15.5 10.0 0.015†
Clinical status on admission and discharge
De novo HF (%) 52.2 52.3 49.8 0.423†
Lung congestion (%) 78.9 78.3 90.3 <0.001†
SBP at admission (mmHg) 131.2±30.3 131.9±30.1 115.3±29.7 <0.001*
SBP at discharge (mmHg) 114.8±17.6 114.8±17.6  - -
DBP at admission (mmHg) 78.6±18.8 79.0±18.6 69.9±20.2 <0.001*
DBP at discharge (mmHg) 67.1±11.5 67.1±11.5  - -
Heart rate at admission (/min) 92.6±26.0 92.5±25.8 95.5±28.3 0.051*
Heart rate at discharge (/min) 76.8±14.2 76.8±14.2  - -
NYHA class III-IV (%) at admission 84.8 84.4 93.7 <0.001†
NYHA class III-IV (%) at discharge 10.8 10.8  -
ECG and echocardiography (%)
RBBB 7.1 6.8 12.6 <0.001†
LBBB 5.2 5.3 4.5 0.563†
Other IVCD 6.2 5.7 14.9 <0.001†
LVEF 37.7±15.6 37.9±15.6 32.6±15.9 <0.001*
Management (%)
Parenteral diuretics 74.9 74.4 85.9 <0.001†
Parenteral inotropes 31.1 28.4 85.1 <0.001†
Parenteral vasodilators 40.9 40.8 43.5 0.376†
ACEIs/ARBs at admission 38.2 38.5 32.7 0.056†
ACEIs/ARBs at discharge 65.9 68.8 <0.001†
Beta-blockers at admission 28.3 28.6 22.7 0.035†
Beta-blockers at discharge 49.9 52.2 <0.001†
AAs at admission 18.8 18.8 17.8 0.695†
AAs at discharge 44.9 46.6 <0.001†
Warfarin at discharge 28.3 29.5 <0.001†
Heart transplantation 1.2 1.2 2.6 0.049‡
Outcomes
Length of hospital stay (days) 9 (1, 311) 9 (1, 311) 12 (1, 305) <0.001*
Total cost per admission (US dollars)ll 9672.2±20969.2 8682.3±17787.0 29462.5±50030.4 <0.001*
Patient liability costs (US dollars) 3047.5±6007.7 2843.8±5533.2 7119.1±11341.5 <0.001*
In-hospital mortality (%) 4.8 
Values are presented as mean±standard deviation, median (min, max) or n (%). *A p value by Wilcoxon rank sum test, †p value by Chi-square test, ‡p value by 
Fisher’s exact test, §includes in-hospital diagnoses, IIUS$ 1 is 1100 Korean won. CMP: cardiomyopathy, HF: heart failure, SBP: systolic blood pressure, DBP: diastolic 
blood pressure, ECG: electrocardiography, RBBB: right bundle branch block, LBBB: left bundle branch block, IVCD: intraventricular conduction delay, LVEF: left 
ventricular ejection fraction, ACEIs: angiotensin converting enzyme inhibitors, ARBs: angiotensin receptor blockers, AAs: aldosterone antagonists
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including 3.0% who were diagnosed with hypertension for the 
first time at the current admission; diabetes was present in 40.0%, 
including 4.7% newly diagnosed; ischemic heart disease (IHD) was 
found in 42.9% with 14.7% newly diagnosed, and chronic renal 
failure (CRF) was identified in 14.3%. Most of the patients had 
lung congestion (78.9%) and experienced dyspnea that was NYHA 
class III or IV (36.9% and 47.9%, respectively) at admission. The 
mean systolic and diastolic blood pressures (SBP and DBP) were 
131.2±30.3 mmHg and 78.6±18.8 mmHg, respectively, and the 
mean pulse rate was 92.6±26.0 beats per minute at admission. The 
percentages of patients with hypotension (SBP <90 mmHg) and 
hypertension (SBP ≥140 mmHg) were 5.3% and 37.2%, respectively. 
Based on electrocardiogram (ECG) results, atrial fibrillation (AF) 
was present in 34.9% of patients at admission, whereas sustained 
ventricular tachycardia/fibrillation was found in 0.6% of patients. 
Pathological Q wave, right bundle branch block (RBBB), and left 
bundle branch block (LBBB) at ECG were present in 13.2%, 7.1%, and 
5.2% of patients, respectively. Hyponatremia (serum sodium <135 
mmEq/L) was present in 21.0% of patients, and the prevalence was 
significantly higher in patients with isolated RHF compared with 
other classifications of HF (27.1% vs. 20.9%, p=0.002). Azotemia 
(serum creatinine ≥2.0 mg/dL) was present in 14.9%, anemia 
(hemoglobin <12 mg/dL) in 42.3%, and leukocytosis (white blood 
cell [WBC] count ≥10000/mm3) in 27.2%. In total, 4842 (93.1%) 
patients had BNP ≥150 pg/mL or NT-proBNP ≥600 pg/mL. The 
laboratory results at admission and discharge are summarized in 
Table 2. The results indicate that IHD (37.6%) was the most frequent 
cause of HF, followed by idiopathic dilated cardiomyopathy (15.3%) 
and valvular heart disease (14.3%). Hypertension was found to be 
the cause in only 4.0% of patients (Fig. 1A). The most frequent 
causes of HF aggravation that led to admission were ischemia 
(26.3%), tachyarrhythmia (20.4%), and infection (19.6%), while a 
Table 2. Laboratory tests on admission and discharge
Admission Discharge
Total Survivor In-hospital death p* Survivor p
WBC (/mL) 8674.4±4081.3 8572.0±3993.8 10709.5±5142.7 <0.001
RDW (%) 14.7±2.1 14.70±2.1 15.2±2.4 0.002
Platelets (/mL) 210534.0±88955.9 211429.8±86168.9 192747.2±131659.5 <0.001
HbA1c (%) 6.8±1.4 6.8±1.4 6.6±1.3 0.511*
Total cholesterol (mg/dL) 151.6±43.2 152.2±42.9 138.8±45.8 <0.001*
Triglycerides (mg/dL) 99.4±59.1 99.43±59.0 99.4±61.5 0.482*
HDL-cholesterol (mg/dL) 41.5±13.9 41.7±13.8 35.0±15.8 <0.001*
Albumin (g/dL) 3.7±0.5 3.7±0.5 3.4±0.6 <0.001*
Sodium (mmol/L) 137.5±4.8 137.6±4.7 135.6±6.4 <0.001* 137.8±4.0 <0.001†
Potassium (mmol/L) 4.4±0.7 4.4±0.7 4.5±0.9 0.007* 4.2±0.5 <0.001†
Uric acid (mg/dL) 7.1±2.9 7.0±2.9 7.9±3.2 <0.001* 6.7±2.7 <0.001‡
Hemoglobin (g/dL) 12.4±2.3 12.4±2.3 12.0±2.3 <0.001* 12.0±2.1 <0.001‡
BUN (mg/dL) 26.2±16.5 25.8±15.9 35.0±23.4 <0.001* 23.9±14.4 <0.001‡
Cr (mg/dL) 1.5±1.5 1.5±1.5 1.9±1.7 <0.001* 1.4±1.3 <0.001‡
Glucose (mg/dL) 155.4±76.9 154.2±75.8 180.6±92.5 <0.001* 117.3±46.2 <0.001‡
hs-CRP (mg/dL) 2.3±4.2 2.2±4.0 4.0±5.8 <0.001* 2.1±3.1 <0.001‡
CRP (mg/dL) 2.4±4.3 2.3±4.1 4.6±6.4 <0.001* 2.1±3.0 <0.001‡
BNP (pg/mL) 1335.1±1301.5 1311.6±1287.5 1795.1±1484.3 <0.001* 848.8±1066.4 <0.001‡
NT-proBNP (pg/mL) 9239.6±10802.4 8954.0±10612.8 14987.6±12839.2 <0.001* 6479.0±8898.6 <0.001‡
CK-MB (ng/mL) 9.5±40.8 8.1±27.6 35.8±134.2 <0.001* 4.3±12.0 <0.001‡
TnI (ng/mL) 2.9±19.9 2.3±17.7 13.2±42.1 <0.001* 2.2±13.3 0.142‡
TnT (ng/mL) 0.2±0.8 0.2±0.7 0.8±1.8 <0.001* 0.3±1.0 0.182‡
Values are presented as mean±standard deviation, median (min, max) or n (%). *A p value by Wilcoxon rank sum test between survivors and non-survivors, 
†p value by paired t-test between survivor levels at admission and discharge, ‡p value by Wilcoxon signed rank test between survivor levels at admission 
and discharge. WBC: white blood cells, RDW: red cell distribution width, HbA1c: hemoglobin A1c, HDL: high density lipoprotein, BUN: blood urea 
nitrogen, Cr: creatinine, hs-CRP: high sensitivity C-reactive protein, CRP: C-reactive protein, BNP: brain natriuretic peptides, NT-proBNP: N-terminal pro-
brain natriuretic peptides, CK-MB: creatine kinase-MB, TnI: troponin I, TnT: troponin T
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definitive cause of aggravation was not found in 13.4% of patients 
(Fig. 1B). Aggravating factors differed significantly based on HF 
etiology (Fig. 1C). In HF patients with non-ischemic causes, the 
aggravating factors were predominantly non-ischemic in origin. 
However, in HF patients with ischemic causes, both ischemic and 
non-ischemic factors were involved in HF aggravation.
Management during hospitalization
The proportion of patients who received evidence-based HF 
medications increased from the point of admission to discharge, 
and 68.8%, 52.2%, and 46.6% of patients were on angiotensin 
converting enzyme inhibitors (ACEIs) or angiotensin receptor 
blockers (ARBs), beta-blockers, or aldosterone antagonists (AAs) 
at discharge, respectively. Following the indication that ACEIs, 
ARBs, and beta-blockers are recommended when LVEF is ≤40% 
and AAs when LVEF is ≤35%,21) 77.6%, 58.0% and 55.1% of the 
patients were treated with ACEIs/ARBs, beta-blockers, or AAs 
at discharge, respectively (Fig. 2A). ARBs were more frequently 
prescribed than ACEIs (ARBs 51.9% vs. ACEIs 47.4%), and only 
0.7% of the population received both medications. Among those 
treated with beta-blockers, 60.8% of patients received carvedilol, 
32.5% bisoprolol, and 3.0% nebivolol. Warfarin was used in 28.3% 
of the overall population and in 51% of the patients with atrial 
fibrillation. Loop diuretics were prescribed for 91.6% of patients 
during admission, primarily through the parenteral route (74.9%). 
Parenteral inotropes were used in 31.1% of patients and parenteral 
vasodilators in 40.9% of patients. Of the total patients, 15.3% 
received mechanical ventilation care, and 7.5% received renal 
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replacement therapy. Red blood cells were transfused in 21.4% 
of patients. Percutaneous coronary intervention and coronary 
artery bypass graft surgery were performed in 10.8% and 2.3% 
of patients, respectively, and an assist device was inserted in 5.9% 
of patients. Detailed pharmacological and non-pharmacological 
treatments during admission are described in Table 3. 
Predictors and outcomes
In-hospital mortality was 4.8%. Heart transplantation was performed 
in 70 patients (1.2%), 7 of whom died during hospitalization. The 
median duration of hospitalization was 9 days. After adjudication, 
79.6% died due to cardiac problems; among them, 62.2% were due 
to pump failure, 3.7% due to sudden cardiac death, and 34.1% due 
to acute coronary syndrome or myocardial infarction (Fig. 3A). 
Sepsis and pneumonia were the most frequent causes of non-
cardiovascular death (37.0% and 28.3%, respectively). There were 
significant differences in demographic and clinical characteristics 
and hospital course between survivors and non-survivors (Table 
1). The patients that died were characterized by advanced age 
(deceased 70.5±14.4 years vs. survivors 68.4±14.5 years, p=0.013), 
lower body mass index (body mass index 22.8±3.8 vs. 23.3±3.9, 
p=0.026), higher diabetes prevalence (51.3% vs. 39.4%, p<0.001), 
and more frequent IHD (58.4% vs. 42.1%, p<0.001) and CRF 
(20.8% vs. 14.0%, p<0.001). They had lower blood pressure (SBP 
115.3±29.7 mmHg vs. 131.9±30.1 mmHg, p<0.001) and more 
severe symptoms at admission (NYHA class III-IV 93.7% vs. 84.4%, 
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Table 3. Hospital treatment
Total Survivor In-hospital death p
Pharmacological treatments
Nitrates
Sustained use 1231 (21.9) 1206 (22.5) 25 (9.3) <0.001*
Transient use 1893 (33.7) 1777 (33.2) 116 (43.1)
Hydralazine
Sustained use 32 (0.6) 32 (0.60) 0 (0.0) 0.102†
Transient use 63 (1.1) 57 (1.1) 6 (2.2)
Loop diuretics
Sustained use 3991 (71.0) 3895 (72.7) 96 (35.7) <0.001*
Transient use 1163 (20.7) 1014 (18.9) 149 (55.4)
Thiazide diuretics
Sustained use 457 (8.1) 451 (8.4) 6 (2.2) 0.001*
Transient use 321 (5.7) 304 (5.7) 17 (6.3)
Amiodarone
Sustained use 422 (7.5) 382 (7.1) 40 (14.9) <0.001*
Transient use 439 (7.8) 367 (6.9) 72 (26.8)
Digoxin
Sustained use 1437 (25.6) 1402 (26.2) 35 (13.0) <0.001*
Transient use 456 (8.1) 394 (7.4) 62 (23.1)
Heparin/LMWH
Sustained use 85 (1.5) 34 (0.6) 51 (19.0) <0.001*
Transient use 2523 (44.9) 2383 (44.5) 140 (52.0)
Warfarin
Sustained use 1591 (28.3) 1580 (29.5) 11 (4.1) <0.001*
Transient use 213 (3.8) 186 (3.5) 27 (10.0)
Aspirin
Sustained use 3019 (53.7) 2948 (55.0) 71 (26.4) <0.001*
Transient use 607 (10.8) 512 (9.6) 95 (35.3)
Statins
Sustained use 2328 (41.4) 2286 (42.7) 42 (15.6) <0.001*
Transient use 273 (4.9) 209 (3.9) 64 (23.8)
Ivabradine
Sustained use 4 (0.1) 4 (0.1) 0 (0.0) 1.000†
Transient use 0 (0.0) 0 (0.0) 0 (0.0) 
Dronedarone
Sustained use 3 (0.1) 3 (0.1) 0 (0.0) 1.000†
Transient use 5 (0.1) 5 (0.1) 0 (0.0)
Insulin 1285 (22.8) 1159 (21.6) 126 (46.8) <0.001*
Oral diabetes medication 1319 (23.5) 1290 (24.1) 29 (10.8) <0.001*
Parenteral medications
Diuretics 4214 (74.9) 3983 (74.4) 231 (85.9) <0.001*
Dobutamine 1279 (22.7) 1100 (20.5) 179 (66.5) <0.001*
Dopamine 986 (17.5) 791 (14.8) 195 (72.5) <0.001*
Milrinone 141 (2.5) 123 (2.3) 18 (6.7) <0.001*
Norepinephrine 528 (9.4) 386 (7.2) 142 (52.8) <0.001*
Nitroprusside 60 (1.1) 55 (1.0) 5 (1.9) 0.210†
Nitroglycerin 2280 (40.5) 2163 (40.4) 117 (43.5) 0.311*
Non-pharmacological treatments
Blood transfusion 1203 (21.4) 1033 (19.3) 170 (63.2) <0.001*
Mechanical ventilation 862 (15.3) 688 (12.9) 174 (64.7) <0.001*
Assisting device 333 (5.9) 234 (4.4) 99 (36.8) <0.001*
IABP 198 (3.5) 143 (2.7) 55 (20.5) <0.001*
LVAD 4 (0.1) 0 (0.0) 4 (1.5) <0.001†
ECMO/PCPS 155 (2.8) 87 (1.6) 68 (25.3) <0.001*
Renal replacement 423 (7.5) 297 (5.6) 126 (46.8) <0.001*
CRT 45 (0.8) 40 (0.8) 5 (1.9) 0.062†
ICD 73 (1.3) 71 (1.3) 2 (0.7) 0.584†
PCI 605 (10.8) 557 (10.4) 48 (17.8) <0.001*
CABG 130 (2.3) 120 (2.2) 10 (3.7) 0.116*
Valve operation 183 (3.3) 174 (3.3) 9 (3.4) 0.930*
Heart transplantation 70 (1.2) 63 (1.2) 7 (2.6) 0.049†
*A p value by Chi-square test, †p value by Fisher’s exact test. LMWH: low-molecular weight heparin, IABP: intra-aortic balloon pump, LVAD: left ventricular 
assistant device, ECMO: extracorporeal membrane oxygenation, PCPS: percutaneous cardiopulmonary support, CRRT: continuous renal replacement therapy, CRT: 
cardiac resynchronization therapy, ICD: implantable cardioverter defibrillator, PCI: percutaneous coronary intervention, CABG. coronary artery bypass graft
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p<0.001). The deceased also had lower LVEF (32.6±15.9% vs. 
37.9±15.6%, p<0.001), stayed longer in the hospital (median 12 days 
vs. 9 days, p<0.001), and had an approximately four times higher 
cost of medical care than those that were discharged. A multivariate 
logistic regression analysis revealed that acute or chronic renal failure 
at admission, lower SBP at admission (<100 mmHg), ischemia as 
an aggravating factor, Q wave, right bundle branch block (RBBB) or 
other intraventricular conduction delay at ECG, advanced age (≥70 
years), hyponatremia (<135 mmEq/L), and leukocytosis (≥10000/mm3) 
at admission were independently related with worsening outcomes, 
while higher body mass index (BMI ≥25 m/kg2) and prior use of beta-
blockers were independent predictors of lower in-hospital mortality 
(Table 4). NYHA functional class III or IV at admission and LVEF no 
more than 40% were also associated with in-hospital mortality 
caused by cardiovascular problems. Infection as an aggravating 
factor was a unique predictor of non-cardiovascular death. Among 
those discharged, post-discharge 30-day mortality was 3.3%, 90-day 
mortality was 8.4%, 180-day mortality was 12.4%, 1-year mortality 
was 18.2%, 2-year mortality was 27.6%, and 3-year mortality was 
34.7% during a median follow-up of 2.2 years. Post-discharge re-
hospitalization for HF aggravation at 30-days, 90-days, 180-days, 
1-year, 2-years, and 3-years was 7.0%, 13.5%, 17.9%, 23.1%, 
30.3%, 36.0% during a median follow-up of 1.5 years, respectively 
(Fig. 3B). 
Discussion
Patient demographics, clinical profiles, and AHF management 
and outcomes 
We compared the results of this study with previous data from 
the KorHF, which also had enrolled patients that were hospitalized 
for AHF in Korea, to assess trends in demographic characteristics, 
clinical profiles, and management and outcomes of AHF in Korea over 
Non-cardiovascular, 
17.1%
Other cardiovascular, 1.9%
Cerebrovascular related, 1.5%
Cardiac related, 79.6%
0 1 2 3 4
Pump failure,
62.2%
ACS/myocardial 
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 34.1%
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3.7%
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Event                 1: Mortality                2: Readmission for HF aggravation
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Fig. 3. Clinical outcomes of acute heart failure. (A) Mechanism of 
in-hospital mortality, (B) Kaplan-Meier survival curve for all-cause 
mortality (blue) and re-hospitalization due to heart failure 
aggravation (red) after discharge. HF: heart failure.
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the last decade.11) The KorHF study enrolled a total of 3200 patients 
from 24 hospitals from June 2004 to April 2009 and had an average 
follow-up of 1.7 years. We extracted data from the hospitals that 
had participated both previously and currently in order to describe 
temporal trends and to limit possible bias that could be caused by 
differences among hospitals (Table 5). The age became older and 
there were more co-morbidities such as hypertension, diabetes 
and chronic lung disease. More patients had history of HF. Clinical 
profiles at admission were similar except for more atrial fibrillation 
presented at admission. There was no significant difference in 
laboratory tests results. In terms of management, more parenteral 
drugs have been used, and guidelines for these prescriptions have 
improved. The most significant changes were seen for frequent use 
of extracorporeal membrane oxygenation (ECMO) or percutaneous 
cardiopulmonary support (PCPS) and heart transplantation. The 
in-hospital mortality was markedly reduced over the past decade, 
while the costs have increased by about 40%. In contrast, one-
year mortality significantly increased in our registry compared to 
the previous registry. However, it was difficult to directly compare 
post-discharge follow-up outcomes between the two registries, 
because our registry validated most of the patient survival with 
the National Insurance data or National Death Records mortality 
(except for 20 patients, including foreigners), while the previous 
registry had not validated mortality, which could have resulted 
in an underestimation of the mortality rate. We assessed the 
impact of mortality validation on in-hospital mortality rate in 
one participating hospital and found that the 6-month mortality 
rate increased from 10.7% to 15% after validation in patients that 
did not complete follow-up due to death. Similarly, our interim 
analysis, published before the mortality validation, reported that 
the 6-month mortality rate was 9.2%, which increased to 12.5% 
in our final analysis after the validation. Thus, we concluded that, 
over the past decade, there has been significant improvement 
in acute clinical care and AHF-related outcomes, although the 
improvements have not yet impacted long-term mortality rates in 
Korea. 
AHF patient profiles in Korea 
Our registry with final enrollment confirms that lower blood 
pressure at admission is a unique characteristic of AHF in Korea, 
and this result was previously suggested by our interim analysis. 
Initial blood pressure at admission was lower than that measured 
by other registries: the mean SBP at admission was 131 mmHg in 
our registry, while it was 147 mmHg in ATTEND,6) 144 mmHg in 
ADHERE,22) and 143 mmHg in OPTIMIZE-HF.8) Hypertension was 
the most common co-morbidity of HF, but it was less frequently 
Table 4. Multivariable logistic regression for in-hospital mortality and multinomial logistic regression for cardiovascular or non-cardiovascular death
All-cause death Cardiovascular death Non-cardiovascular death
Adjusted OR (95% CI) p Adjusted OR (95% CI)1) p Adjusted OR (95% CI)1) p
Elderly (≥70 years) 1.593 (1.138:2.231) 0.007 
Body mass index (≥25 kg/m2) 0.609 (0.410:0.906) 0.014 0.649 (0.417:1.009) 0.055 0.435 (0.190:0.998) 0.049 
SBP (<100 mmHg) 2.447 (1.688:3.546) <0.001 2.331 (1.558:3.497) <0.001 2.242 (1.081:4.651) 0.030 
NYHA III or IV 2.658 (1.145:6.171) 0.023 0.423 (0.194:0.920) 0.030 
Chronic renal failure 5.67 (3.656:8.794) <0.001 4.770 (2.903:7.835) <0.001 8.830 (3.555:21.930) <0.001
Acute renal failure at admission 13.315 (9.09:19.503) <0.001 12.236 (7.995:18.727) <0.001 19.234 (8.413:43.978) <0.001
Ischemia as an aggravating factor 1.585 (1.131:2.222) 0.008 2.082 (1.413:3.068) <0.001 1.142 (0.541:2.410) 0.727 
Infection as an aggravating factor 1.388 (0.893:2.158) 0.145 2.906 (1.512:5.585) 0.001 
Beta-blockers before admission 0.657 (0.453:0.951) 0.026 
Q wave at ECG 2.067 (1.409:3.034) <0.001 2.296 (1.522:3.465) <0.001 1.024 (0.387:2.706) 0.962 
RBBB at ECG 1.781 (1.082:2.930) 0.023 
Other IVCD at ECG 2.695 (1.699:4.275) <0.001 2.216 (1.322:3.713) 0.003 3.304 (1.366:7.993) 0.008 
Leukocytosis 1.6 (1.153:2.219) 0.005 1.461 (1.011:2.113) 0.049 1.731 (0.918:3.265) 0.090 
Hyponatremia 1.806 (1.303:2.503) <0.001 1.835 (1.274:2.646) 0.001 1.319 (0.688:2.532) 0.405 
LVEF ≤40% 1.560 (1.025:2.375) 0.038 0.550 (0.288:1.049) 0.070 
C-statistics 0.865
OR: odds ratio, CI: confidential interval, SBP: systolic blood pressure, ECG: electrocardiography, RBBB: right bundle branch block, IVCD: intraventricular 
conduction delay, Leukocytosis: white blood cell count ≥10000/mm3, Hyponatremia: serum sodium <135 mmEq/L, LVEF: left ventricular ejection fraction
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Table 5. KorAHF and KorHF comparisons   
KorAHF (2011-2014) (n=5625) KorHF (2004-2009) (n=1788)*
Demographics
Age (years) 68.5±14.5 66.5±15.1
Male (%) 53.2 52.3 
Body mass index (m/kg2) 23.3±3.9 23.2±4.0
Co-morbidities† (%)
Hypertension 59.1 48.7 
Diabetes 35.3 29.9 
Previous MI 16.8 16.5 
Previous HF history 43.7 37.5 
Chronic lung disease 11.3 4.8 
Cerebrovascular disease 15.2 17.9 
Chronic renal failure 14.3 12.5 
Etiology and aggravation (%)
Ischemic CMP 37.6 35.9 
Idiopathic dilated DCMP 15.3 21.7 
Unknown etiology 4.0 8.5 
Aggravation by ischemia 26.3 28.8 
Aggravation by hypertension 2.8 5.8 
Clinical status on admission and discharge
SBP at admission (mmHg) 131.2±30.3 132.0±30.1
DBP at admission (mmHg) 78.6±18.8 78.4±18.6
Heart rate at admission (/min) 92.6±26.0 91.7±25.4
NYHA class III-IV (%) 84.8 84.6 
Atrial fibrillation at admission (%) 34.9 25.6 
LVEF (%) 37.7±15.6 37.9±15.2
Laboratory tests at admission
White blood cell count (/mL) 8674.4±4081.3 9417.6±4527.9
Hemoglobin (g/dL) 12.4±2.3 12.5±2.4
Serum creatinine (mg/dL) 1.5±1.5 1.5±1.5
Serum sodium (mmol/L) 137.5±4.8 137.3±5.1
BNP (pg/mL) 1335.1±1301.5 1336.7±1977.2
NT-proBNP (pg/mL) 9239.6±10802.4 8964.4±9962.1
LBBB at ECG (%) 7.1 6.4 
RBBB at ECG (%) 5.2 5.4 
Management (%)
Parenteral diuretics 74.9 63.9 
Parenteral inotropes 31.1 24.0 
Parenteral vasodilators 40.9 37.2 
ACEIs/ARBs at discharge 68.8 68.8 
Beta-blockers at discharge 52.2 43.7 
AAs at discharge 46.6 37.1 
ECMO/PCPS 2.8 0.8 
Heart transplantation 1.2 0.3 
Outcomes
Total costs for hospital care‡ (US dollars) 9672.2±20969.2 6805.5±12146.8
Patient liability costs‡ (US dollars) 3047.5±6007.7 2483.4±4726.3
Length of stay (day) 9 (1, 311) 9 (1, 403)
In-hospital mortality (%) 4.8 7.6
One-year follow-up mortality (%) 18.2 8.4§
Values are presented as mean±standard deviation or number (%). *Population of hospitals participating KorAHF, †from past medical history, ‡US$ 1 is 1100 
Korean won, §mortality data was not validated in all patients. KorAHF: Korean acute heart failure, KorHF: Korean heart failure, MI: myocardial infarction, HF: 
heart failure, CMP: cardiomyopathy, SBP: systolic blood pressure, DBP: diastolic blood pressure, LVEF: left ventricular ejection fraction, BNP: brain natriuretic 
peptides, NT-proBNP: N-terminal pro-brain natriuretic peptides, RBBB: right bundle branch block, LBBB: left bundle branch block, ECG: electrocardiography, 
ACEIs: angiotensin converting enzymes, ARBs: angiotensin receptor blockers, AAs: aldosterone antagonists, ECMO: extracorporeal membrane oxygenation, 
PCPS: percutaneous cardiopulmonary support
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combined in our patients compared with those in other registries 
(62% vs. 71% in ATTEND, 74% in ADHERE, 71% in OPTIMIZE-HF, 63% 
in EHFSII.23) The prevalence of HF with hypertension as an etiology 
(4%) was also lower than in other registries, such as ATTEND (18%), 
OPTIMIZE-HF (23%), and EHFSII (11%). Another interesting feature 
of AHF patients in Korea was the prevalence of bundle branch 
block (BBB) on ECG. Our interim analysis revealed that only a small 
proportion of patients had received cardiac resynchronization 
therapy (CRT). We investigated the reason for this and found that 
the prevalence of both LBBB and RBBB was lower in our patients 
compared with those in Western countries. After adjudication by a 
cardiologist, we determined that the prevalence of LBBB and RBBB 
were 7.1% and 5.2%, respectively, in our registry. The Romanian 
Acute Heart Failure Syndromes (RO-AHFS) registry reported that 
16.7% and 10.6% patients had LBBB and RBBB, respectively.24) 
Among those admitted to the intensive care unit at Henry Ford 
Hospital in the United States, 13.2% had LBBB and 7.3% had 
RBBB,25) among those hospitalized for HF in UK hospitals, 15% had 
LBBB and 7% had RBBB.26) This lower prevalence of BBB in Korea 
might partially explain the underused CRT in Korea. These unique 
features of AHF in Korea were also supported by the analysis of the 
KorHF population (Table 5).
Medical therapy and guideline adherence for HF patients
The unique characteristics of our patients, particularly characteristics 
related to blood pressure, could affect the use of evidence-based 
medications, such as ARBs, ACEIs, beta-blockers, AAs, and other 
drugs, such as parenteral diuretics and inotropes. As demonstrated 
by interim analysis, there was less frequent use of ACEIs/ARBs in our 
registry compared with other registries (68.8% vs. 83% in ADHERE, 
80% in EHFSII, and 77% in the ESC-HF Long-Term registry).27) The 
less frequent prescription of beta-blockers was more remarkable. In 
our registry, beta-blockers were prescribed in 52.2% of cases while 
they were prescribed in 80% of ADHERE cases, 61% in EHFSII, and 
71.8% in the ESC-HF Long-Term registry. Although Asians are often 
reported to have higher sensitivity to beta-blockers compared to 
other populations, 64% of Korean HF patients are reported to 
have active adrenalin receptor 1 polymorphism, which requires a 
33% increased dose of beta blocker to achieve the same range of 
heart rate reduction compared with the less active genotype.28) The 
prescription rate of AAs was moderate (46.6% in KorAHF vs. 33% in 
ADHERE, 48% in EHFSII, 55.3% in the ESC-HF Long-Term registry). 
However, the statistics from these studies do not directly infer a 
problem with guideline adherence in Korea, since the indications 
and contraindications for these evidence-based medications might 
differ from registry to registry. For example, if we consider LVEF 
as an indication of the prescription of neurohormonal blockages 
and exclude those patients who received heart transplant, the 
prescription rates of ACEIs or ARBs, beta-blockers, and AAs would 
increase to 77.6%, 58.0%, and 55.1%, respectively. Thus, the 
degree of adherence might be much greater when we consider the 
contraindications of ACEIs/ARBs or beta-blockers, such as lower 
blood pressure, renal failure, or chronic obstructive lung diseases. 
An interesting finding was that the prescription rate of evidence-
based medical therapy has increased significantly after the results 
of our interim analysis were released, and the interim analysis 
indicated that the prescription rate of evidence-medications in 
Korea is lower than that in other registries (Fig. 2B). This implies that 
establishing a registry, objectively and comprehensively assessing 
current practice patterns, and sharing results among clinicians 
could improve performance.  
Study limitations
There were several limitations to this study. First, the KorAHF 
is not a clinical trial but a patient registry. Therefore, assessment, 
management, and follow-up regimens have not been standardized 
and vary by institution. Unmeasured variables may have influenced 
the results. Second, because only tertiary educational hospitals 
participated in this registry and were not selected based on 
statistical measures according to population dynamics, our 
cohort might not represent the general population of HF patients 
in Korea. Third, while in-hospital mortality was confirmed by an 
independent events committee, the causes of post-discharge 
mortality and re-hospitalization were not validated. Because this 
result is different than that of all-cause mortality, there are missing 
values for re-hospitalization statistics. Finally, laboratory tests and 
echocardiographic results were not centralized. 
Conclusion
In conclusion, our analysis of AHF patients in Korea demonstrates 
that Korean patients have lower blood pressure and lower BBB 
prevalence at admission, which could possibly affect the clinical 
practice pattern and the degree of adherence to current clinical 
guidelines. Invasive treatments such as ECMO/PCPS and heart 
transplantation have been performed more frequently compared 
to past studies, which showed increased acute AHF-related 
clinical outcomes, which remain to be addressed. However, the 
long-term prognosis of HF is still poor, and the burden of medical 
costs remains high. Our study suggests the need for further 
rigorous studies to determine the most cost-effective approach 
for HF management and to better assess the long-term HF-related 
outcomes using critical examination of current clinical practice 
patterns. A comprehensive study will ultimately help establish a 
patient-friendly clinical care system for HF in Korea. 
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